# US 2020/0392209 A1 · Stabilized liquid anti-rsv antibody formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392209 A1
- Document ID: US20200392209A1
- Status: Published application
- Kind: A1
- Application number: 16/807,420
- Filed: 2020-03-03
- Published: 2020-12-17
- Earliest claimed: 2002-06-14
- Assignees: Arexis AB
- Applicants: Arexis AB
- Inventors: Cynthia N. Oliver; Erica Shane; Benjamin S. Isaacs; Christian B. Allan; Stephen T. Chang
- Web page: https://patentgrep.com/patent/US20200392209A1

## CPC

- C07K 16/11: Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0043: {Nose}
- A61K 39/39591: {Stabilisation, fragmentation}
- A61K 39/42: viral
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 37/04: Immunostimulants
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.

## Claims

### Claim 1

A liquid SYNAGIS® formulation comprising: (a) at least 15 mg/ml of SYNAGIS®, or an antigen-binding fragment; and (b) histidine in an aqueous carrier, wherein said formulation is substantially free of surfactant, inorganic salts or other excipients.

### Claim at position 2

2-39. (canceled)

### Claim 40 (depends on 1)

A method of preventing, treating or ameliorating one or more symptoms associated with a RSV infection in a subject, said method comprising administering a prophylactically or therapeutically effective amount of the formulation of claim 1.

### Claim at position 4

41-45. (canceled)

### Claim 46 (depends on 1)

A method of purifying and formulating a liquid SYNAGIS® formulation of claim 1, wherein the histidine concentration is about 1 mM to about 100 mM and wherein said formulation is substantially free of surfactant, inorganic salts or other excipients, and wherein the method comprises maintaining the SYNAGIS®, or an antigen-binding fragment thereof, in an aqueous solution at all times during preparation.

### Claim 47

A method of preventing, treating, or ameliorating one or more symptoms associated with a RSV infection in a subject, said method comprising administering a prophylactically or therapeutically effective amount of a liquid formulation comprising an antibody or antigen-binding fragment thereof;
wherein the antibody or antigen-binding fragment thereof specifically binds to an epitope in the A antigenic site of the F protein of the Respiratory Syncytial Virus (RSV) and comprises a heavy chain CDR1 sequence comprising the sequence TSGMSVG (SEQ ID NO:1), a heavy chain CDR2 sequence comprising the sequence DIWWDDKKDYNPSLKS (SEQ ID NO:2), a heavy chain CDR3 sequence comprising the sequence SMITNWYFDV (SEQ ID NO:3), a light chain CDR1 sequence comprising the sequence KCQLSVGYMH (SEQ ID NO:4), a light chain CDR2 sequence comprising the sequence DTSKLAS (SEQ ID NO:5), and a light chain CDR3 sequence comprising the sequence FQGSGYPFT (SEQ ID NO:6); and
wherein the formulation comprises:
at least 15 mg/ml of the antibody or antigen-binding fragment thereof; and histidine in an aqueous carrier, and wherein said formulation is substantially free of surfactant, inorganic salts or other excipients.

### Claim 48 (depends on 47)

The method of claim 47, wherein the histidine concentration is about 1 mM to about 100 mM.

### Claim 49 (depends on 47)

The method of claim 47, wherein histidine is at a concentration of about 10 mM to about 30 mM.

### Claim 50 (depends on 47)

The method of claim 47, wherein histidine is at a concentration of about 25 mM.

### Claim 51 (depends on 47)

The method of claim 47, wherein the formulation has a pH of about 5.0 to about 7.0.

### Claim 52 (depends on 47)

The method of claim 47, wherein the formulation has a pH of about 6.0.

### Claim 53 (depends on 47)

The method of claim 47, wherein the formulation further comprises glycine at a concentration of less than 150 mM glycine, less than 100 mM glycine, less than 50 mM glycine, less than 3.0 mM glycine, less than 2.0 mM glycine, or less than 1.8 mM glycine.

### Claim 54 (depends on 47)

The method of claim 47, wherein the formulation further comprises glycine at a concentration of about 1.6 mM.

### Claim 55 (depends on 47)

The method of claim 47, wherein the formulation and does not contain mannitol.

### Claim 56 (depends on 47)

The method of claim 47, wherein the subject is an infant born prematurely.

### Claim 57 (depends on 56)

The method of claim 56, wherein the infant is born prematurely at less than 35 weeks gestational age.

### Claim 58 (depends on 47)

The method of claim 47, wherein the subject is a child with bronchopulmonary dysplasia.

### Claim 59 (depends on 47)

The method of claim 47, wherein the subject is a child with a congenital heart disease.

### Claim 60 (depends on 47)

The method of claim 47, wherein the subject is a child with acquired or congenital immunodeficiency.

### Claim 61 (depends on 47)

The method of claim 47, wherein the subject is a child with cystic fibrosis.

### Claim 62 (depends on 47)

The method of claim 47, comprising monthly administration of the liquid formulation.

### Claim 63

A method of preventing, treating, or ameliorating one or more symptoms associated with a RSV infection in a subject, said method comprising administering a prophylactically or therapeutically effective amount of a liquid formulation comprising an antibody or antigen-binding fragment thereof:
wherein the antibody or antigen-binding fragment thereof specifically binds to an epitope in the A antigenic site of the F protein of the Respiratory Syncytial Virus (RSV) and comprises a heavy chain CDR1 sequence comprising the sequence TSGMSVG (SEQ ID NO:1), a heavy chain CDR2 sequence comprising the sequence DIWWDDKKDYNPSLKS (SEQ ID NO:2), a heavy chain CDR3 sequence comprising the sequence SMITNWYFDV (SEQ ID NO:3), a light chain CDR1 sequence comprising the sequence KCQLSVGYMH (SEQ ID NO:4), a light chain CDR2 sequence comprising the sequence DTSKLAS (SEQ ID NO:5), and a light chain CDR3 sequence comprising the sequence FQGSGYPFT (SEQ ID NO:6); and
wherein the formulation comprises:
103±3 mg/ml of the antibody or antigen-binding fragment thereof;
histidine at a concentration of about 25 mM; and
glycine at a concentration of about 1.6 mM;
wherein said formulation has a pH of about 6.0 and wherein said formulation is substantially free of surfactant, inorganic salts or other excipients.

### Claim 64 (depends on 63)

The method of claim 63, wherein the formulation does not contain mannitol.
